These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 30854892)

  • 21. Shortening duration of ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections: A retrospective study.
    Fink DL; Collins S; Barret R; Pollara G; Marks M; Logan S
    PLoS One; 2019; 14(9):e0223130. PubMed ID: 31557236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of fosfomycin in the treatment of bacterial infections.
    Hutzler R; Fernandes V; Muñoz D; Rozentraub A
    Chemotherapy; 1977; 23 Suppl 1():358-64. PubMed ID: 832537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Fosfomycin: past, present and future].
    Baylan O
    Mikrobiyol Bul; 2010 Apr; 44(2):311-21. PubMed ID: 20549968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fosfomycin: Mechanism and Resistance.
    Silver LL
    Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 28062557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fosfomycin-trometamol for Urinary Tract Infections in Kidney Transplant Recipients.
    Ten Doesschate T; van Werkhoven H; Meijvis S; Stalenhoef J; van Zuilen A; de Vries A; Bonten M
    Transplantation; 2019 Jun; 103(6):1272-1276. PubMed ID: 30130327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.
    Rosso-Fernández C; Sojo-Dorado J; Barriga A; Lavín-Alconero L; Palacios Z; López-Hernández I; Merino V; Camean M; Pascual A; Rodríguez-Baño J;
    BMJ Open; 2015 Mar; 5(3):e007363. PubMed ID: 25829373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Fosfomycin in the treatment of some infectious diseases].
    Aceti A; Vullo V; Ferone U; Delia S
    Clin Ter; 1979 Jan; 88(1):61-6. PubMed ID: 436378
    [No Abstract]   [Full Text] [Related]  

  • 28. Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature.
    Grabein B; Graninger W; Rodríguez Baño J; Dinh A; Liesenfeld DB
    Clin Microbiol Infect; 2017 Jun; 23(6):363-372. PubMed ID: 27956267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fosfomycin for UTIs.
    Drug Ther Bull; 2016 Oct; 54(10):114-117. PubMed ID: 27737907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-vitro susceptibility of quinolone-resistant clinical isolates of Escherichia coli to fosfomycin trometamol.
    Ungheri D; Albini E; Belluco G
    J Chemother; 2002 Jun; 14(3):237-40. PubMed ID: 12120876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria.
    Khan IU; Mirza IA; Ikram A; Ali S; Hussain A; Ghafoor T
    J Coll Physicians Surg Pak; 2014 Dec; 24(12):914-7. PubMed ID: 25523727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Urinary tract infections: cystitis, pyelonephritis, urosepsis].
    Fünfstück R; Wagenlehner FM; Olschläger T; Naber KG
    Dtsch Med Wochenschr; 2012 Feb; 137(5):198-201. PubMed ID: 22278690
    [No Abstract]   [Full Text] [Related]  

  • 33. [The role of fosfomycin in the management of urinary tract infections].
    Zaitsev AV; Kolontarev KB
    Urologiia; 2017 Sep; (4):91-96. PubMed ID: 28952700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of respiratory infections with fosfomycin.
    Menéndez A; Tutor A; Sousa AS
    Chemotherapy; 1977; 23 Suppl 1():348-57. PubMed ID: 832536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fosfomycin for Treatment of Prostatitis: New Tricks for Old Dogs.
    Grayson ML; Macesic N; Trevillyan J; Ellis AG; Zeglinski PT; Hewitt NH; Gardiner BJ; Frauman AG
    Clin Infect Dis; 2015 Oct; 61(7):1141-3. PubMed ID: 26063723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections.
    Roussos N; Karageorgopoulos DE; Samonis G; Falagas ME
    Int J Antimicrob Agents; 2009 Dec; 34(6):506-15. PubMed ID: 19828298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers.
    Wenzler E; Ellis-Grosse EJ; Rodvold KA
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections.
    Ceran N; Mert D; Kocdogan FY; Erdem I; Adalati R; Ozyurek S; Goktas P
    J Infect Chemother; 2010 Dec; 16(6):424-30. PubMed ID: 20585969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fosfomycin: A Revisited Antibiotic for Urinary Tract Infections.
    Parikh FS
    J Assoc Physicians India; 2017 Sep; 65(9):11. PubMed ID: 29313569
    [No Abstract]   [Full Text] [Related]  

  • 40. Progressive increase of resistance in Enterobacteriaceae urinary isolates from kidney transplant recipients over the past decade: narrowing of the therapeutic options.
    Origüen J; Fernández-Ruiz M; López-Medrano F; Ruiz-Merlo T; González E; Morales JM; Fiorante S; San-Juan R; Villa J; Orellana MÁ; Andrés A; Aguado JM
    Transpl Infect Dis; 2016 Aug; 18(4):575-84. PubMed ID: 27373698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.